Acelrx Pharmaceuticals Inc., of Redwood City, Calif., said it priced its underwritten public offering of 7.27 million shares at $2.75 each, with gross proceeds expected to be approximately $20 million. The underwriters have been granted a 30-day option to purchase up to 1.09 million additional shares. The company intends to use the net proceeds for general corporate purposes, including funding of early commercialization efforts. The company's shares (NASDAQ:ACRX) closed Friday at $3.28, down 16 percent.

Intrommune Therapeutics Inc., of New York, said it closed a series A preferred equity financing, led by Red Bear Angels. The investment will support the company's IND to the FDA for INT-301, an oral mucosal immunotherapy product for the long-term treatment of peanut allergy using a patent-protected daily use toothpaste.

Omeros Corp., of Seattle, said it priced an offering of $210 million of its 6.25 percent convertible senior notes due 2023 in a private offering to qualified institutional buyers. It has granted the initial purchasers of the notes an option to purchase up to an additional $40 million of the notes on the same terms and conditions.

Sarepta Therapeutics Inc., of Cambridge, Mass., said it priced an underwritten public offering of 3.81 million shares at $131 each. In addition, it has granted the underwriters a 30-day option to purchase up to an additional 572,550 shares. The company anticipates the gross proceeds from the offering to be approximately $500 million, excluding any exercise of the underwriters' option to purchase additional shares. It intends to use the net proceeds principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities, including the potential licensing or acquisition of complementary products and technologies, and other general corporate purposes. Shares of Sarepta (NASDAQ:SRPT) fell $7.54 to close Friday at $125.46.

Taiwan Liposome Co. Ltd., of Taipei City, Taiwan, filed with the SEC to amend its IPO. It is now offering 5 million American depositary shares (ADSs), with each ADS representing two of its common shares and priced at $5.80. The company is focused on the development and commercialization of nanomedicines that combine a lipid-assembled drug delivery platform with approved active pharmaceutical ingredients. In its filing, it said it has assembled a product candidate portfolio that targets pain management, ophthalmology and oncology. It anticipates that it will have four lead product candidates in late- or pivotal-stage clinical trials by the end of 2020. The company has applied to list its ADSs on Nasdaq under the symbol TLC.